Partner, Life Sciences Senior Analyst
Areas of focus: Life Sciences
In January 2019, Adam was selected as a senior analyst in RSM’s cutting-edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions influencing middle market leaders. Adam’s focus is on the life sciences industry.
Summary of experience
Adam has more than 10 years of accounting and finance experience, serving private equity backed and private closely-held companies in the middle market. He focuses on high-growth companies that are globally active in the technology, SaaS and consumer products industries. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their businesses.
Prior to joining RSM, Adam was a manager of assurance and risk advisory services. In addition to leading financial statement audits, he performed fraud investigations, business process analysis, and the development of effective oversight and governance environments.
Adam is an instructor at the regional and national level, and is well-versed in the application of ASC 606 revenue recognition for the technology and consumer products industries.
Professional Affiliations and Credentials
- Certified Public Accountant
- Certified Fraud Examiner
- American Institute of Certified Public Accountants
- Bachelor of Science, business administration, University of Arizona
- Masters of Accountancy, University of Arizona
Cyberthreats are here to stay for life sciences companies, but staying a step ahead of the criminals can ensure the good guys win the day.
Middle market biopharma companies face business challenges as they expand and launch new products. What are these issues and opportunities?
THE REAL ECONOMY
Governments and businesses—including the middle market firms that constitute the real economy—will face new challenges.
Here are some areas in which CMOs, CROs and life sciences companies with established product pipelines might consider investing right now.
Biden plans to expand Medicare, a move that the Congressional Budget Office estimates would cut drug spending by $450 billion over 10 years.
With the election approaching, RSM is looking at the economic stakes and the key issues for the life sciences industry.
We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.
For companies that may have dealt with a lab closure because of the pandemic, Scientist.com allows research to continue.
More promise, more problems: Cyberattacks threaten life sciences companies researching COVID-19 vaccine.
Learn about opportunities for life sciences foreign direct investment (FDI) into the United States with this complimentary webcast.